PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT05478603
- Locations
- 🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting
- Conditions
- Breast Neoplasms
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 440
- Registration Number
- NCT05478590
- Locations
- 🇵🇱
Ambulatorium Chemioterapii Centrum Onkologii, Bydgoszcz, Poland
🇵🇱Wojewodzki Szpital Zespolony w Elblągu - oddzial onkologii, Elblag, Poland
🇵🇱Oddział onkologii Szpital Specjalistyczny im. H. Klimontowicza, Gorlice, Poland
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12557
- Registration Number
- NCT05477524
- Locations
- 🇺🇸
Hunterdon Medical Center, Flemington, New Jersey, United States
🇺🇸Care Access - Essex, Essex, Connecticut, United States
🇺🇸Care Access Mobile Site, New Shoreham, Rhode Island, United States
Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding
- Conditions
- Non-valvular Atrial Fibrillation
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120722
- Registration Number
- NCT05471505
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)
- Conditions
- Severe Uncontrolled Atopic Dermatitis
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05466578
A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT05463952
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05462639
- Locations
- 🇺🇸
Baptist Hospital of Miami, Miami, Florida, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California, United States
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- Conditions
- Pneumonia
- Interventions
- Diagnostic Test: Diagnostic test on urine samples
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12500
- Registration Number
- NCT05452941
- Locations
- 🇪🇸
Hospital Universitari i Politecnic La Fe, Valencia, València, Spain
🇺🇸Kaiser Permanete Baldwin Park, Baldwin Park, California, United States
🇺🇸Kaiser Permanete Downey, Downey, California, United States
A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark
- Conditions
- Breast Cancer
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1054
- Registration Number
- NCT05452798
- Locations
- 🇩🇰
Danish Breast Cancer Group, Copenhagen, Denmark
A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT05446142
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States